Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBP NASDAQ:ENTA NASDAQ:INBX NASDAQ:PGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$30.50+0.5%$28.12$16.10▼$33.62$1.41B1.41533,849 shs438,235 shsENTAEnanta Pharmaceuticals$11.07-1.9%$13.51$6.43▼$17.15$328M0.97215,721 shs158,110 shsINBXInhibrx Biosciences$89.13+2.4%$98.12$13.26▼$155.29$1.28B3.33462,923 shs194,456 shsPGENPrecigen$3.57-0.3%$4.08$1.38▼$5.47$1.28B1.064.52 million shs4.63 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma+0.49%-0.59%+3.39%+20.41%+29.68%ENTAEnanta Pharmaceuticals-1.86%-12.63%-27.84%-20.65%+48.19%INBXInhibrx Biosciences+2.44%-10.23%-33.66%+24.43%+540.30%PGENPrecigen-0.28%-13.35%-15.20%+1.71%+138.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$30.50+0.5%$28.12$16.10▼$33.62$1.41B1.41533,849 shs438,235 shsENTAEnanta Pharmaceuticals$11.07-1.9%$13.51$6.43▼$17.15$328M0.97215,721 shs158,110 shsINBXInhibrx Biosciences$89.13+2.4%$98.12$13.26▼$155.29$1.28B3.33462,923 shs194,456 shsPGENPrecigen$3.57-0.3%$4.08$1.38▼$5.47$1.28B1.064.52 million shs4.63 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma+0.49%-0.59%+3.39%+20.41%+29.68%ENTAEnanta Pharmaceuticals-1.86%-12.63%-27.84%-20.65%+48.19%INBXInhibrx Biosciences+2.44%-10.23%-33.66%+24.43%+540.30%PGENPrecigen-0.28%-13.35%-15.20%+1.71%+138.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 2.82Moderate Buy$43.3842.21% UpsideENTAEnanta Pharmaceuticals 2.75Moderate Buy$20.2983.25% UpsideINBXInhibrx Biosciences 2.33Hold$150.0068.29% UpsidePGENPrecigen 2.33Hold$12.50250.14% UpsideCurrent Analyst Ratings BreakdownLatest ENTA, AVBP, PGEN, and INBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026AVBPArriVent BioPharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$43.00 ➝ $45.005/28/2026PGENPrecigen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $14.005/22/2026AVBPArriVent BioPharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/14/2026PGENPrecigen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.005/14/2026PGENPrecigen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/14/2026PGENPrecigen Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$9.00 ➝ $11.005/13/2026AVBPArriVent BioPharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$45.00 ➝ $43.005/4/2026AVBPArriVent BioPharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/24/2026AVBPArriVent BioPharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$33.00 ➝ $45.004/24/2026INBXInhibrx Biosciences Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026PGENPrecigen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A$7.44 per shareN/AENTAEnanta Pharmaceuticals$65.32M4.93N/AN/A$3.03 per share3.65INBXInhibrx Biosciences$1.30M1,005.80N/AN/A$0.55 per share162.05PGENPrecigen$9.68M131.48N/AN/A$0.06 per share59.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$166.31M-$3.47N/AN/AN/AN/A-48.98%-45.44%8/10/2026 (Estimated)ENTAEnanta Pharmaceuticals-$81.89M-$2.59N/AN/AN/A-89.56%-64.04%-20.22%8/10/2026 (Confirmed)INBXInhibrx Biosciences-$140.05M-$8.39N/AN/AN/AN/A-563.90%-72.32%8/12/2026 (Estimated)PGENPrecigen-$250.64M-$1.18N/A14.28N/A-646.99%717.50%58.48%8/11/2026 (Estimated)Latest ENTA, AVBP, PGEN, and INBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026INBXInhibrx Biosciences-$1.6750-$2.15-$0.4750-$2.15N/AN/A5/13/2026Q1 2026PGENPrecigen-$0.03-$0.02+$0.01-$0.02$20.81 million$23.25 million5/11/2026Q1 2026AVBPArriVent BioPharma-$0.88-$0.96-$0.08-$0.96N/AN/A5/11/2026Q2 2026ENTAEnanta Pharmaceuticals-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million3/25/2026Q4 2025PGENPrecigen-$0.10-$0.01+$0.09-$0.01$8.29 million$4.57 million3/19/2026Q4 2025INBXInhibrx Biosciences-$2.08-$2.11-$0.03-$2.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A13.9513.95ENTAEnanta PharmaceuticalsN/A3.843.84INBXInhibrx Biosciences12.586.466.46PGENPrecigen4.624.824.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%ENTAEnanta Pharmaceuticals94.99%INBXInhibrx Biosciences82.46%PGENPrecigen33.51%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharma8.58%ENTAEnanta Pharmaceuticals11.48%INBXInhibrx Biosciences18.26%PGENPrecigen47.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4046.58 million42.58 millionN/AENTAEnanta Pharmaceuticals16029.08 million25.74 millionOptionableINBXInhibrx Biosciences16614.67 million11.99 millionOptionablePGENPrecigen190356.51 million188.59 millionOptionableENTA, AVBP, PGEN, and INBX HeadlinesRecent News About These CompaniesPrecigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8 at 11:38 AM | seekingalpha.comPrecigen (NASDAQ:PGEN) CEO Helen Sabzevari Sells 119,250 SharesJune 3, 2026 | americanbankingnews.comPrecigen (NASDAQ:PGEN) Insider Donald Lehr Sells 29,131 SharesJune 2, 2026 | insidertrades.comPrecigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?June 1, 2026 | zacks.comHC Wainwright Has Bullish Forecast for Precigen Q3 EarningsJune 1, 2026 | americanbankingnews.comPrecigen (NASDAQ:PGEN) Downgraded by Wall Street Zen to HoldMay 31, 2026 | americanbankingnews.comPrecigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 YearsMay 30, 2026 | prnewswire.comPrecigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United StatesMay 27, 2026 | prnewswire.comPrecigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare ConferenceMay 26, 2026 | prnewswire.comPrecigen (PGEN): The Best Penny Stock to Buy for Long TermMay 22, 2026 | insidermonkey.comPrecigen: Why I Am More Cautious After The Q1 Beat (Downgrade)May 21, 2026 | seekingalpha.comEquities Analysts Set Expectations for Precigen Q3 EarningsMay 18, 2026 | marketbeat.comEarnings Beat: Precigen, Inc. (NASDAQ:PGEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 16, 2026 | finance.yahoo.comPrecigen (NASDAQ:PGEN) Stock, Earnings Estimates, EPS, And RevenueMay 14, 2026 | benzinga.comPrecigen Earnings Call Highlights PAPZIMEOS Launch SurgeMay 14, 2026 | tipranks.comPrecigen IncMay 14, 2026 | edition.cnn.comPrecigen Inc (PGEN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...May 14, 2026 | finance.yahoo.comPrecigen’s lead cancer therapy is fueling a massive stock rally — here’s what Wall Street sees nextMay 14, 2026 | msn.comPrecigen jumps after Q1 beat as Papzimeos launch momentum takes holdMay 14, 2026 | msn.comPrecigen: Full Commercial Validation And Room To RunMay 14, 2026 | seekingalpha.comWhy is Precigen stock surging today?May 14, 2026 | za.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026Rocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?By Ryan Hasson | June 4, 2026Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked NameBy Leo Miller | June 1, 2026The Pentagon's AI Pivot Supercharges Defense StocksBy Jeffrey Neal Johnson | May 19, 2026Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record HighsBy Thomas Hughes | May 15, 2026ENTA, AVBP, PGEN, and INBX Company DescriptionsArriVent BioPharma NASDAQ:AVBP$30.50 +0.15 (+0.49%) Closing price 06/8/2026 04:00 PM EasternExtended Trading$30.58 +0.07 (+0.25%) As of 06/8/2026 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Enanta Pharmaceuticals NASDAQ:ENTA$11.07 -0.21 (-1.86%) Closing price 06/8/2026 04:00 PM EasternExtended Trading$11.07 0.00 (0.00%) As of 06/8/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Inhibrx Biosciences NASDAQ:INBX$89.13 +2.12 (+2.44%) Closing price 06/8/2026 04:00 PM EasternExtended Trading$89.38 +0.25 (+0.27%) As of 06/8/2026 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Precigen NASDAQ:PGEN$3.57 -0.01 (-0.28%) Closing price 06/8/2026 04:00 PM EasternExtended Trading$3.56 -0.01 (-0.42%) As of 06/8/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Technology Stocks Just Got Cheaper—Here Are 5 Mega-Caps Worth a Closer Look Amprius Insiders Are Selling: Should Investors Be Worried? MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? Planet Labs: Coming Back Down to Earth Docusign: Another Beat, Another Selloff—Why the Analysts Are Wrong A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Nebius Is Up Nearly 175% This Year—Here's What's Driving the Latest Run Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
